Clinical Trial Update: Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study [Phase 2]

View source ↗

Summary

Phase II single-arm study evaluating furmonertinib plus bevacizumab as first-line therapy for EGFR-mutant non-small cell lung cancer with brain metastases; curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Leptomeningeal Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Furmonertinib (furmonertinib)

Snippet

Sponsor: Li-kun Chen | Conditions: Non-small Cell Lung Cancer (NSCLC), EGFR Mutation-Positive Lung Cancer | Phase 2 | Status: RECRUITING